Humacyte to Present at the Piper Sandler 36th Annual Healthcare Conference
Humacyte (Nasdaq: HUMA) announced its participation in the Piper Sandler 36th Annual Healthcare Conference in New York. Dr. Laura Niklason, the company's Founder, President, and CEO, will engage in a fireside chat presentation on December 5, 2024, at 8:00 a.m. EST at The Lotte New York Palace. The presentation will be accessible via webcast, with a replay available on the company's website. Management will also be available for one-on-one meetings during the conference.
Humacyte (Nasdaq: HUMA) ha annunciato la sua partecipazione alla 36ª Conferenza Annuale sulla Salute di Piper Sandler a New York. La Dott.ssa Laura Niklason, Fondatrice, Presidente e CEO dell'azienda, parteciperà a una presentazione in forma di chat il 5 dicembre 2024, alle 8:00 EST presso il Lotte New York Palace. La presentazione sarà accessibile in streaming, con una registrazione disponibile sul sito web dell'azienda. Il management sarà inoltre disponibile per incontri one-to-one durante la conferenza.
Humacyte (Nasdaq: HUMA) anunció su participación en la 36ª Conferencia Anual de Salud de Piper Sandler en Nueva York. La Dra. Laura Niklason, fundadora, presidenta y CEO de la empresa, participará en una presentación tipo 'fireside chat' el 5 de diciembre de 2024, a las 8:00 a.m. EST en el Lotte New York Palace. La presentación será accesible a través de un webcast, con una repetición disponible en el sitio web de la empresa. La dirección también estará disponible para reuniones individuales durante la conferencia.
Humacyte (Nasdaq: HUMA)는 뉴욕에서 열리는 Piper Sandler 제36회 연례 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 회사의 창립자이자 CEO인 로라 니클라손 박사가 2024년 12월 5일 오전 8시 EST에 롯데 뉴욕 팔래스에서 화상 대화 형식의 발표를 진행할 예정입니다. 발표는 웹캐스트를 통해 액세스 가능하며, 회사 웹사이트에서 재생이 가능합니다. 경영진도 컨퍼런스 동안 일대일 회의에 참석할 것입니다.
Humacyte (Nasdaq: HUMA) a annoncé sa participation à la 36e Conférence Annuelle de Santé de Piper Sandler à New York. Dr Laura Niklason, fondatrice, présidente et PDG de l'entreprise, participera à une présentation sous forme de chat intime le 5 décembre 2024 à 8h00 EST au Lotte New York Palace. La présentation sera accessible par webdiffusion, avec une rediffusion disponible sur le site internet de l'entreprise. La direction sera également disponible pour des réunions individuelles pendant la conférence.
Humacyte (Nasdaq: HUMA) gab seine Teilnahme an der 36. jährlichen Healthcare-Konferenz von Piper Sandler in New York bekannt. Dr. Laura Niklason, die Gründerin, Präsidentin und CEO des Unternehmens, wird am 5. Dezember 2024 um 8:00 Uhr EST im Lotte New York Palace an einer Gesprächsrunde teilnehmen. Die Präsentation wird über einen Webcast zugänglich sein, und eine Aufzeichnung wird auf der Website des Unternehmens verfügbar sein. Die Unternehmensführung wird außerdem während der Konferenz für persönliche Gespräche zur Verfügung stehen.
- None.
- None.
DURHAM, N.C., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Founder, President, and Chief Executive Officer, will participate in a fireside chat presentation at the Piper Sandler 36th Annual Healthcare Conference, in New York, NY on Thursday, December 5, 2024. Management will also be available for one-on-one meetings.
Event: Piper Sandler 36th Annual Healthcare Conference
Location: The Lotte New York Palace, NY
Presentation: Thursday, December 5, 8:00 a.m. EST
Webcast: https://event.webcasts.com/
A replay will be available for a limited time following the presentation on the Events & Presentations portion of the Humacyte website.
About Humacyte
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. Humacyte develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Humacyte’s initial product candidates, a portfolio of ATEVs, are currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous (AV) access for hemodialysis, and peripheral artery disease. A Biologics License Application for the ATEV in the vascular trauma indication is currently under review by the FDA and was granted Priority Review. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm ATEV for AV access in hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation. Humacyte’s 6mm ATEV for urgent arterial repair following extremity vascular trauma and for advanced PAD also have received an RMAT designations. The ATEV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.
Humacyte Investor Contact:
Joyce Allaire
LifeSci Advisors LLC
+1-617-435-6602
jallaire@lifesciadvisors.com
investors@humacyte.com
Humacyte Media Contact:
Rich Luchette
Precision Strategies
+1-202-845-3924
rich@precisionstrategies.com
media@humacyte.com
FAQ
When is Humacyte (HUMA) presenting at the Piper Sandler Healthcare Conference 2024?
Where can I watch Humacyte's (HUMA) Piper Sandler Conference presentation?
What type of presentation will Humacyte (HUMA) give at the Piper Sandler Conference?
Where is the Piper Sandler Healthcare Conference 2024 being held for Humacyte (HUMA)?
